Downregulated ANXA11 expression is associated with cisplatin resistance in ovarian cancer, and pointed as a useful biomarker to predict chemoresistance to platinum-based therapies and early tumor recurrence (Song et al., 2007). This evidence concerns the gene ANXA11 and neoplasm.